<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03294200</url>
  </required_header>
  <id_info>
    <org_study_id>CIP 2101-01</org_study_id>
    <nct_id>NCT03294200</nct_id>
  </id_info>
  <brief_title>Clinical Trial Evaluation of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System</brief_title>
  <official_title>Clinical Trial Evaluation of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4Tech Cardio Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4Tech Cardio Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to generate safety and performance data for the 4Tech TriCinch&#xD;
      Coil System in symptomatic patients suffering from significant functional tricuspid&#xD;
      regurgitation with annular dilatation.&#xD;
&#xD;
      The TriCinch Coil System is a percutaneous catheter-based medical device for tricuspid valve&#xD;
      repair.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    As per sponsor&#xD;
  </why_stopped>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Actual">July 14, 2020</completion_date>
  <primary_completion_date type="Actual">July 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality of the Per Protocol cohort at 30 days post procedure.</measure>
    <time_frame>30 days post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of individual adverse events related to the system or procedure.</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic changes compared to Baseline by means of echocardiographic semi-quantitative and quantitative measures</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional changes as compared to Baseline for New York Heart Association (NYHA) classification</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Heart Failure event post-procedure defined as a heart failure hospitalization or a heart failure hospitalization equivalent</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise tolerance (Six Minute Walk Test)</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life evaluation (Kansas City Cardiomyopathy Questionnaire).</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Tricinch Coil System treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TriCinch Coil System implantation</intervention_name>
    <description>Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.</description>
    <arm_group_label>Tricinch Coil System treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Moderate to severe functional tricuspid regurgitation (TR) defined as: TR severity 2+&#xD;
             to 4+ (according to semi-quantitative echocardiographic color flow doppler&#xD;
             evaluation); and Annular diameter ≥ 40 mm confirmed by echocardiography&#xD;
&#xD;
          2. ≥ 18 years old&#xD;
&#xD;
          3. Subject has read and signed the informed consent prior to study related procedures.&#xD;
&#xD;
          4. Willing and able to comply with all required follow-up evaluations and assessments.&#xD;
&#xD;
          5. The 'Heart Team' assessment recommends TriCinch Coil Implantation&#xD;
&#xD;
          6. New York Heart Associate Classification ≥ II.&#xD;
&#xD;
          7. Left Ventricular Ejection Fraction ≥ 30%.&#xD;
&#xD;
          8. Heart failure symptoms (such as fluid retention and severe oedema, liver stasis)&#xD;
             despite on optimized medical therapy by the local heart team; at minimum subject on&#xD;
             diuretic use&#xD;
&#xD;
          9. Subject has suitable anatomy for investigational device implantation as per imaging&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently participating in another investigational drug or device study.&#xD;
&#xD;
          2. Subject with Systolic pulmonary arterial pressure (sPAP) &gt; 60mmHg as measured by&#xD;
             Transthoracic Echocardiography (TTE)&#xD;
&#xD;
          3. Subject requiring another cardiac procedure in the framework of the index procedure;&#xD;
             subject requiring a percutaneous procedure within 30 days before or after the&#xD;
             procedure or a cardiac surgical procedure within 3 months before or after the&#xD;
             procedure&#xD;
&#xD;
          4. Moderate or Severe tricuspid valve stenosis (defined as a mean gradient ≥5 mmHg at&#xD;
             normal heart rate)&#xD;
&#xD;
          5. Aortic, mitral and/or pulmonic valve stenosis and/or regurgitation more than or equal&#xD;
             to moderate&#xD;
&#xD;
          6. Mitral valve stenosis and/or regurgitation more than moderate&#xD;
&#xD;
          7. Intra-cardiac thrombus, mass or vegetation requiring active treatment.&#xD;
&#xD;
          8. Implanted inferior vena cava (IVC) filter.&#xD;
&#xD;
          9. Prior tricuspid repair or tricuspid replacement&#xD;
&#xD;
         10. Known allergy to contrast media, silicone, PET, Co-Cr, stainless steel or nitinol that&#xD;
             cannot be adequately pre-medicated&#xD;
&#xD;
         11. History of cardiac transplantation&#xD;
&#xD;
         12. Contraindication to Transthoracic/Transoesophageal Echocardiography (TTE/TOE).&#xD;
&#xD;
         13. Endocarditis or severe infection within 12 months of scheduled implant procedure&#xD;
&#xD;
         14. Myocardial Infarction (MI) or known unstable angina within the 30 days prior to the&#xD;
             index procedure&#xD;
&#xD;
         15. Cerebro Vascular Accident within the previous 6 months&#xD;
&#xD;
         16. Hemodynamic instability or on IV inotropes&#xD;
&#xD;
         17. Contraindication to anticoagulant therapy and antiplatelet therapy&#xD;
&#xD;
         18. Bleeding disorders or hypercoagulable condition (at risk of blood clots)&#xD;
&#xD;
         19. Active peptic ulcer or active GI bleeding within 3 months of scheduled implant&#xD;
             procedure&#xD;
&#xD;
         20. Severe renal impairment or on dialysis&#xD;
&#xD;
         21. Life expectancy less than 12 months.&#xD;
&#xD;
         22. Acute anemia&#xD;
&#xD;
         23. Chronic Oral Steroid Use ≥ 6 months&#xD;
&#xD;
         24. Pregnant or lactating female of childbearing potential with a positive pregnancy test&#xD;
             24 hours before any study-related radiation exposure&#xD;
&#xD;
         25. Pulmonary embolism within the last 6 months&#xD;
&#xD;
         26. Tricuspid Valve Tethering distance &gt; 10 mm&#xD;
&#xD;
         27. Presence of trans-tricuspid pacemaker or defibrillator leads which are determined as&#xD;
             immobile or interfering with the procedure, as evaluated by echocardiography.&#xD;
&#xD;
         28. Contra-indicated for blood transfusion or refuses transfusion&#xD;
&#xD;
         29. Patient undergoing emergency treatment&#xD;
&#xD;
         30. Patient without appropriate venous access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Heart</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge-Oostende AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CardioVascular Center Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton &amp; Sussex University Hospitals - Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX9 3DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

